Latest Market Entry Strategy News

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

SkyCity Entertainment Group reported a 22% drop in underlying EBITDA for FY26, impacted by regulatory costs and carded play rollout, while progressing asset sales and preparing for New Zealand's online casino market.

1414 Degrees secured $8.45 million funding and inked major agreements to commercialise its SiNTL battery technology across AI data centres, drones, satellites and defence sectors.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Harvest Technology Group has secured independent validation of its Nodestream platform's strong fit within the US defence sector, highlighting a clear pathway for market entry focused on bandwidth-constrained communications.

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

Memphasys Limited confirms uninterrupted operations across the Middle East and North Africa, securing new orders and advancing regulatory approvals despite ongoing regional tensions.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Firebird Metals has advanced its manganese-rich battery materials with a patented energy-saving kiln and precursor cathode outperforming Chinese benchmarks, while planning an Australian Demonstration Plant to break into Western markets.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.